Radiopharmaceutical manufacturer International Isotopes last month posted its fiscal 1998 results (end-December). The Denton, TX, firm reported revenues of $2 million for the year, a dramatic increase over 1997’s $136,000. The company attributed the
Radiopharmaceutical manufacturer International Isotopes last month posted its fiscal 1998 results (end-December). The Denton, TX, firm reported revenues of $2 million for the year, a dramatic increase over 1997s $136,000. The company attributed the increase to its International Isotopes Idaho subsidiarys product sales, as well as income from development contracts. The companys net loss for the year was $5.5 million, compared with the previous years $4.4 million loss.
In other news, the firm last month formed a joint venture with GammaPlus, an Austin, TX-based subsidiary of Lucas Medical Associates that operates short-lived radiopharmaceutical manufacturing centers. The joint venture will be called GammaPlus DFW, and will manufacture and distribute PET radiopharmaceuticals, including fluorodeoxyglucose F-18 (FDG). GammaPlus DFW will produce FDG with International Isotopes cyclotron, and expects to begin distributing the isotope within the next few months, according to Carl Seidel, president and CEO of International Isotopes. Distribution will be primarily to hospitals and clinics in the Dallas/Fort Worth area, Seidel said.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.